Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus PT from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $13.75.

Several research analysts have recently commented on TBPH shares. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th.

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The disclosure for this sale can be found here. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC grew its holdings in shares of Theravance Biopharma by 3.7% during the first quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 1,359 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 3,532 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Theravance Biopharma by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,824 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Theravance Biopharma by 28.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 4,990 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Theravance Biopharma by 11.7% during the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 6,026 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 1.9 %

TBPH opened at $8.21 on Wednesday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The business has a fifty day simple moving average of $8.44 and a 200-day simple moving average of $8.83. The firm has a market cap of $401.63 million, a P/E ratio of -9.55 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. Sell-side analysts expect that Theravance Biopharma will post -1.04 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.